Biberach, Germany

Wolfgang Resemann

This inventor holds 5 USPTO granted patents. Top assignees: Boehringer Ingelheim Vetmedica Gmbh, Dr. Karl Thomae Gmbh. Active years: 1986-1997.


% Patents Active = 100.0

Average Co-Inventor Count = 3.3

ph-index = 2

Forward Citations = 12(Granted Patents)


Company Filing History:


Years Active: 1986-1997

Loading Chart...
5 patents (USPTO):Explore Patents

Title: Wolfgang Resemann: Innovator in Pharmaceutical Chemistry

Introduction

Wolfgang Resemann is a notable inventor based in Biberach, Germany. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the separation of enantiomers. With a total of 5 patents to his name, Resemann's work has had a considerable impact on the development of pharmaceutical compositions.

Latest Patents

Among his latest patents is the invention related to the separation of enantiomers of cimaterol and (-)-cimaterol. This invention encompasses the addition salts thereof and processes for preparing them. Furthermore, it highlights their use in pharmaceutical compositions and animal feeds. This innovative approach has the potential to enhance the efficacy of pharmaceutical products.

Career Highlights

Throughout his career, Wolfgang Resemann has worked with prominent companies in the pharmaceutical industry. Notably, he has been associated with Boehringer Ingelheim Vetmedica GmbH and Dr. Karl Thomae GmbH. His experience in these organizations has allowed him to refine his expertise in pharmaceutical innovations.

Collaborations

Resemann has collaborated with esteemed colleagues, including Adolf Durr and Gunther Engelhardt. These partnerships have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Wolfgang Resemann's contributions to pharmaceutical chemistry through his innovative patents and collaborations have established him as a significant figure in the field. His work continues to influence the development of effective pharmaceutical solutions.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…